ALROUGHANI , Raed

No description

Background and purpose: The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); however, randomized clinical trials evaluate only short-term treatment effects on disability. This study aimed to define criteria for 6-month confirmed disability progression events of MS with a high probability of...

Introduction: Multiple sclerosis (MS) treatment interruptions are common and leave patients vulnerable to breakthrough disease activity. The safe duration of the 'switchover time' for different therapies is not known.Aims: To evaluate the rate and predictors of return of disease activity after cessation of disease-modifying therapy.Methods:...

Objectives: To evaluate the rate of return of disease activity after cessation of multiple sclerosis (MS) disease-modifying therapy. Methods: This was a retrospective cohort study from two large observational MS registries: MSBase and OFSEP. Patients with relapsing-remitting MS who had ceased a disease-modifying therapy and were followed up for...

Background: A delayed onset of treatment effect, termed therapeutic lag, may influence the assessment of treatment response in some patient subgroups.Objectives: The objective of this study is to explore the associations of patient and disease characteristics with therapeutic lag on relapses and disability accumulation.Methods: Data from...